Skip to main content

Table 2 Impact of baseline characteristics on patient prognosis in the training cohort (N = 203)

From: Prognostic value of ERBB4 expression in patients with triple negative breast cancer

  Training N = 203 (%) 5-year disease relapse-free survival (%) p-value
(Log-rank)
Age (median) 46.4 ± 10.2   
 Range 23.5-74.1   0.633
  < 40 years 48 (23.6) 81.2  
  ≥ 40 years 155 (76.4) 86.4  
Histology    0.507
 IDCa 180 (88.7) 85.5  
 Others 23 (11.3) 82.9  
Stage    <0.001
 I 55 (27.1) 90.9  
 IIA 94 (46.3) 91.5  
 IIB 33 (16.3) 78.8  
 IIIA 13 (6.4) 67.7  
 IIIB 0 (0)   
 IIIC 8 (3.9) 25.0  
 Unknown 0 (0)   
Nuclear grade    0.258
 1 2 (1.0) 50.0  
 2 47 (23.2) 82.8  
 3 145 (71.4) 86.9  
 Unknown 9 (4.4) 77.8  
Histologic grade    0.704
 1 3 (1.5) 100.0  
 2 45 (22.2) 84.4  
 3 144 (70.9) 86.0  
 Unknown 11 (5.4) 72.7  
EGFR (median: 7.0)    0.084
 Low 104 (51.2) 90.3  
 High 99 (48.8) 79.8  
ERBB2 (median: 9.0)    0.402
 Low 102 (50.2) 88.2  
 High 101 (49.8) 82.1  
ERBB3 (median: 7.2)    0.106
 Low 102 (50.2) 90.2  
 High 101 (49.8) 80.1  
ERBB4 (median: 1.3)    0.022
 Low 102 (50.2) 90.1  
 High 101 (49.8) 80.2  
ESR1 (median: 4.4)    0.689
 Low 102 (50.2) 84.2  
 High 101 (49.8) 86.1  
Adjuvant chemotherapy    0.001
 CMF1 86 (42.4) 90.7  
 FAC2 58 (28.6) 86.0  
 AC3 17 (8.4) 100.0  
 AC –T4 41 (20.2) 65.9  
 Unknown 1 (0.5) 100.0  
Adjuvant RTx5    0.093
 Yes 130 (64.0) 83.0  
 No 73 (36.0) 89.0  
  1. aInvasive ductal carcinoma, 1Cyclophosphamide /Methotrexate/Fluorouracil, 2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide, 4Taxane, 5Radiotherapy